NORD statement in response to American Patients First, the Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs

Written by Laura Mullen on May 15, 2018

The National Organization for Rare Disorders (NORD) today issued the following statement in response to American Patients First, the Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs:

Patients with rare diseases are frequently disproportionately affected by high drug prices.  Rare diseases tend to be… Read More